Paying user area
Try for free
Humana Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Analysis of Solvency Ratios
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Total Asset Turnover since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Humana Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
- Reported Net Income Attributable to Humana
-
The reported net income exhibited an increase from 2019 to 2020, rising from 2,707 million US dollars to 3,367 million US dollars, which indicates a period of growth. However, starting from 2021, there was a downward trend in reported net income. The figure declined to 2,933 million US dollars in 2021, further decreased slightly to 2,806 million US dollars in 2022, and continued to decline to 2,489 million US dollars in 2023. This suggests challenges impacting profitability in the later years of the period analyzed.
- Adjusted Net Income Attributable to Humana
-
The adjusted net income followed a similar initial upward trajectory, increasing from 3,026 million US dollars in 2019 to 3,601 million US dollars in 2020. However, unlike the reported net income, the adjusted net income experienced a more pronounced decline in the subsequent years. It dropped substantially to 2,578 million US dollars in 2021 and plummeted further to 1,460 million US dollars in 2022, marking the lowest point in the five-year period. In 2023, the adjusted net income showed a significant rebound to 2,794 million US dollars but remained below the figures seen in 2019 and 2020.
- Comparative Observations
-
Across the period, adjusted net income consistently exceeded reported net income for most years except for 2022 when adjusted income was substantially lower. The wider fluctuations in adjusted net income compared to reported net income suggest that adjustments such as one-time events, impairments, or other non-operational factors had considerable impact during the period, especially in 2022. The overall trends depict initial growth followed by a period of volatility and decline, with partial recovery in the final year observed.
Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
The analysis of the financial data reveals several significant trends across the reported and adjusted profitability indicators for the time span from 2019 to 2023.
- Net Profit Margin
- The reported net profit margin shows a consistent decline, dropping from 4.2% in 2019 to 2.36% in 2023. The adjusted net profit margin exhibits a similar downward trend, declining from 4.7% in 2019 to a low of 1.58% in 2022, before recovering somewhat to 2.65% in 2023. This pattern suggests increasing pressure on profitability margins, with some improvement in the most recent year after a period of sharper decline.
- Return on Equity (ROE)
- The reported ROE follows a downward trajectory over the five-year period, decreasing from 22.49% in 2019 to 15.31% in 2023. Adjusted ROE echoes this pattern but with more volatility, starting at 25.14% in 2019, peaking slightly in 2020 at 26.23%, then plunging sharply to 9.54% in 2022 before recovering to 17.18% in 2023. The volatility in adjusted ROE may reflect adjustments for non-recurring items or investment-related factors impacting equity returns.
- Return on Assets (ROA)
- The reported ROA has steadily declined from 9.31% in 2019 to 5.29% in 2023, indicating diminished efficiency in asset utilization for generating profits. Adjusted ROA also decreases markedly from 10.41% in 2019 to 3.39% in 2022 before rebounding to 5.94% in 2023. This rebound in adjusted ROA suggests some recovery in asset efficiency after a significant dip.
Overall, both reported and adjusted financial metrics demonstrate a general decline in profitability and efficiency from 2019 through the bulk of the 2021-2022 period. The year 2023 shows preliminary signs of stabilization or partial recovery, particularly in adjusted margins and returns, which may indicate management’s efforts to address margins and asset performance are beginning to take effect. The divergence and volatility observed in adjusted measures emphasize the impact of certain adjustments and highlight the importance of considering both reported and adjusted figures for a comprehensive assessment.
Humana Inc., Profitability Ratios: Reported vs. Adjusted
Adjusted Net Profit Margin
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2023 Calculations
1 Net profit margin = 100 × Net income attributable to Humana ÷ External revenues
= 100 × ÷ =
2 Adjusted net profit margin = 100 × Adjusted net income attributable to Humana ÷ External revenues
= 100 × ÷ =
Analysis of the financial data reveals several notable trends over the five-year period ending December 31, 2023.
- Net Income
- The reported net income attributable shows an initial increase from 2,707 million USD in 2019 to a peak of 3,367 million USD in 2020, representing a strong growth year. However, a decline follows in the subsequent years, with figures falling to 2,933 million USD in 2021, 2,806 million USD in 2022, and further down to 2,489 million USD in 2023. This indicates a downward trajectory in reported profitability after 2020.
- The adjusted net income attributable reflects a similar pattern, starting higher at 3,026 million USD in 2019 and rising to 3,601 million USD in 2020. Unlike the reported metric, the adjusted net income experiences a sharper decline in 2021 and 2022, dropping to 2,578 million USD and 1,460 million USD respectively. There is a notable recovery in 2023 to 2,794 million USD, though this remains below the peak levels of 2019 and 2020.
- Net Profit Margins
- The reported net profit margin shows a slight improvement from 4.2% in 2019 to 4.43% in 2020, indicating increased profitability relative to revenue that year. From 2021 onward, the margin declines steadily, reaching 3.54% in 2021, 3.03% in 2022, and 2.36% in 2023. This trend suggests that profitability relative to revenue has been weakening since 2020.
- The adjusted net profit margin follows a parallel trend but at generally higher levels. Beginning at 4.7% in 2019 and rising slightly to 4.74% in 2020, it then declines more sharply to 3.11% in 2021 and further to 1.58% in 2022. A partial recovery is observed in 2023, with the margin increasing to 2.65%, yet it remains below the margins reported in the earlier years of the period examined.
Overall, the data suggest that the company experienced strong financial performance growth in 2020, followed by a period of contraction and instability in both net income and profit margins. The adjusted figures highlight more pronounced volatility, particularly with a significant dip in 2022, indicating that adjustments for investment-related items have had material impacts on reported profitability. The partial rebound in 2023 suggests efforts toward financial stabilization, but the margins and net income remain below peak levels achieved earlier in the period.
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2023 Calculations
1 ROE = 100 × Net income attributable to Humana ÷ Stockholders’ equity
= 100 × ÷ =
2 Adjusted ROE = 100 × Adjusted net income attributable to Humana ÷ Stockholders’ equity
= 100 × ÷ =
- Net Income Trends
- The reported net income attributable to the company showed growth from 2019 to 2020, increasing from $2,707 million to $3,367 million. However, it declined in the subsequent years, falling to $2,933 million in 2021, $2,806 million in 2022, and further to $2,489 million by 2023. In contrast, the adjusted net income followed a different trajectory. It peaked in 2020 at $3,601 million, then experienced a sharp decline to $2,578 million in 2021, followed by a significant drop to $1,460 million in 2022. A rebound occurred in 2023, with adjusted net income rising to $2,794 million, nearly returning to the 2019 level.
- Return on Equity (ROE) Patterns
- Reported ROE increased from 22.49% in 2019 to 24.53% in 2020, indicating improved profitability relative to shareholder equity. Thereafter, it declined steadily to 18.24% in 2021 and stabilized around 18.33% in 2022 before decreasing to 15.31% in 2023. Adjusted ROE displayed a similar pattern initially, rising to 26.23% in 2020 from 25.14% in 2019. It then decreased markedly to 16.03% in 2021 and further to 9.54% in 2022, reflecting reduced adjusted profitability. A partial recovery was observed in 2023, with adjusted ROE improving to 17.18%, though still below earlier peak levels.
- Insights and Overall Observations
- The data indicates a peak in profitability and returns in 2020, which was followed by a downturn through 2022 in both reported and adjusted metrics. This decline is more pronounced for adjusted figures, especially in 2022, suggesting underlying operational or investment adjustments affecting profitability. The rebound in 2023 adjusted net income and adjusted ROE signals some recovery, though reported net income and ROE continue to trend lower. The divergence between reported and adjusted figures in recent years may warrant further investigation into the nature of adjustments and their impacts on financial performance.
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
2023 Calculations
1 ROA = 100 × Net income attributable to Humana ÷ Total assets
= 100 × ÷ =
2 Adjusted ROA = 100 × Adjusted net income attributable to Humana ÷ Total assets
= 100 × ÷ =
The financial performance of the company demonstrates noticeable fluctuations over the five-year period from 2019 to 2023. A detailed review of reported and adjusted net income, as well as corresponding returns on assets (ROA), reveals a varying trend reflective of changing operational and investment circumstances.
- Net Income Trends
- The reported net income attributable to the company reached a peak in 2020 at 3,367 million US dollars, following consistent growth from 2,707 million in 2019. However, it declined over the subsequent three years to 2,489 million by 2023. Adjusted net income followed a somewhat similar pattern, peaking at 3,601 million in 2020, then experiencing a sharp decline to 1,460 million in 2022 before rebounding to 2,794 million in 2023. This considerable volatility in adjusted figures suggests significant adjustments or one-off factors impacting profitability during these years.
- Return on Assets (ROA)
- The reported ROA showed a steady decrease after a slight increase from 9.31% in 2019 to 9.63% in 2020, then dropping continuously to 5.29% in 2023. The adjusted ROA mirrored this pattern with a high of 10.41% in 2019, maintaining a similar level in 2020, followed by a sharp decline to 3.39% in 2022, and then a modest recovery to 5.94% in 2023. The decline in both reported and adjusted ROA indicates reduced efficiency in utilizing assets to generate earnings during the latter part of the period.
- Insights and Implications
- The stronger performance in 2020 across both reported and adjusted metrics may reflect favorable market conditions or successful operational strategies during that year. The subsequent decline, particularly pronounced in adjusted net income and adjusted ROA, points to potential challenges such as investment losses, restructuring costs, or other non-recurring events adversely affecting profitability. The partial recovery seen in 2023 adjusted net income and adjusted ROA suggests some stabilization or improvement in these underlying factors. Overall, the trends highlight the importance of distinguishing between reported and adjusted data to fully comprehend the company’s financial health and to assess the impact of exceptional items on performance measures.